A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. Supplementary Figures and Tables

Published: 17-03-2021| Version 1 | DOI: 10.17632/b6sct48jmb.1
Contributor:
Brett King

Description

Supplementary Figures 1-7. Supplementary Tables 1-5

Files